NVCR analyst estimates
NovoCure (NVCR) analyst ratings, the average price target and its range, and every firm's latest call.
NVCR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 24, 2026 | H.C. Wainwright | NovoCure Ltd. (NVCR) PT Lowered to $32 at H.C. Wainwright | $32.00 |
| Jul 24, 2026 | Wedbush | Novocure price target raised to $20 from $18 at Wedbush | $20.00 |
| Jul 23, 2026 | H.C. Wainwright | Novocure price target raised to $52 from $46 at H.C. Wainwright | $52.00 |
| Jun 18, 2026 | H.C. Wainwright | Novocure price target lowered to $46 from $48 at H.C. Wainwright | $46.00 |
| Feb 12, 2026 | H.C. Wainwright | Novocure price target raised to $47 from $39 at H.C. Wainwright | $47.00 |
| Jan 13, 2026 | H.C. Wainwright | Novocure price target lowered to $39 from $42 at H.C. Wainwright | $39.00 |
| Jan 5, 2026 | Evercore ISI | Novocure price target lowered to $20 from $22 at Evercore ISI | $20.00 |
| Oct 30, 2025 | H.C. Wainwright | Novocure price target raised to $42 from $38 at H.C. Wainwright | $42.00 |
| Jul 24, 2025 | Wells Fargo | Novocure downgraded to Equal Weight from Overweight at Wells Fargo | $14.50 |
| Dec 2, 2024 | Evercore ISI | Evercore ISI Upgrades NovoCure Ltd. (NVCR) to Outperform 'into Panova readout on asymmetric risk/reward' | $30.00 |
| Oct 16, 2024 | H.C. Wainwright | H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy | $30.00 |
| Jul 26, 2024 | H.C. Wainwright | NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright | $24.00 |
| May 3, 2024 | H.C. Wainwright | NovoCure Ltd. (NVCR) PT Lowered to $22 at H.C. Wainwright | $22.00 |
| May 2, 2024 | Evercore ISI | NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI | $14.50 |
| Apr 10, 2024 | Piper Sandler | NovoCure Ltd. (NVCR) PT Raised to $28 at Piper Sandler | $28.00 |
- 5 firms rate NVCR: 2 buy, 3 hold, 0 sell.
- The average price target is $26.00 from 2 analysts, from $20.00 to $32.00.
Updated 2026-11-03 11:32 UTC